Less Ads, More Data, More Tools Register for FREE

Pin to quick picksTissue Regenix Group Regulatory News (TRX)

  • This share is currently suspended. It was suspended at a price of 7.23
  • There is currently no data for TRX

Acquisition

2 May 2006 10:25

Torex Retail PLC02 May 2006 TOREX RETAIL PLC ("Torex Retail" or "the Group") EXPANSION OF PETROLEUM ACTIVITIES WITH ACQUISITION OF LEADING UK SERVICE PROVIDER Torex Retail, an international market leader in the provision of innovative ITsolutions, is pleased to announce the acquisition of TQIPS Limited ("TQIPS"), aleading provider of project management and services to UK petroleum retailers. The initial consideration payable of £7.25 million is to be satisfied by theissue to the vendors of 7.25 million ordinary shares in Torex Retail. Furtherconsideration of up to £3.5 million will be payable to the vendors dependentupon the profitability of TQIPS in the two years ending 31 December 2007. Anyadditional consideration payable will be satisfied through the issue of TorexRetail ordinary shares. Application has been made to the London Stock Market for the 7,250,000 sharesissued on completion to be admitted to trading on AIM. It is expected thatadmission will occur on 5 May 2006. Brendan Kavanagh , Head of Worldwide Petroleum for Torex Retail, commented : "Strategically TQIPS is a very important acquisition and a natural expansion ofour petroleum retail business. TQIPS has an unrivalled reputation for serviceand completes our overall service offering to the Major Oil Companies and majorsupermarket chains. Their blue chip customer list including Tesco, Asda,Morrisons, BP and Texaco further strengthens our base in this market whichalready includes Jet, Esso, Shell, Somerfields, Maxol, Lakeside Group and alarge number of independent dealers." This acquisition positions us extremely well to win significantly more businessin this expanding sector, including our target of achieving major contract winsfor LUCAS Petroleum." Ends. For further information please contact: Torex Retail plc: +44 (0) 870 300 6061 Brendan Kavanagh , Head of Worldwide Petroleum Mark Pearman , Group Finance Director Citigate Dewe Rogerson: +44 (0) 20 7638 9571 Seb Hoyle This information is provided by RNS The company news service from the London Stock Exchange
Date   Source Headline
13th Nov 20249:32 amRNSForm 8.3 - Tissue Regenix Group Plc
12th Nov 20244:05 pmRNSForm 8 (OPD) (Tissue Regenix Group Plc)
12th Nov 20248:46 amRNSForm 8.5 (EPT/NON-RI)
11th Nov 20249:17 amRNSForm 8.5 (EPT/NON-RI)
7th Nov 20249:59 amRNSForm 8.5 (EPT/NON-RI) - Tissue Regenix Group PLC
6th Nov 20241:37 pmRNSForm 8.3 - Tissue Regenix Group PLC
6th Nov 20248:52 amRNSForm 8.5 (EPT/NON-RI)
5th Nov 20242:24 pmRNSForm 8.3 - Tissue Regenix Group PLC
5th Nov 202411:32 amRNSForm 8.5 (EPT/NON-RI)
4th Nov 20244:36 pmRNSResponse to media speculation
10th Sep 20247:00 amRNSInterim results for the six months ended 30 June
18th Jul 20243:52 pmRNSGrant of share options
16th Jul 20247:00 amRNSHalf-Year Trading Update
3rd Jul 20241:16 pmRNSHolding(s) in Company
24th Jun 20244:12 pmRNSHolding(s) in Company
18th Jun 20245:15 pmRNSExercise of Options, Director Dealing and TVR
14th Jun 20247:00 amRNSBuilding purchase
25th Apr 20242:27 pmRNSResult of AGM
10th Apr 20247:15 amEQSHardman & Co Research on Tissue Regenix (TRX): Six consecutive periods of >20% growth
5th Apr 20243:52 pmRNSHolding(s) in Company
19th Mar 20247:00 amRNSFinal results for the year ended 31 December 2023
1st Mar 20247:00 amRNSNotice of Results
6th Feb 20247:00 amRNSFirst EU shipment & new distributor agreements
29th Jan 20243:02 pmRNSHolding(s) in Company
25th Jan 20247:00 amRNSTrading update for 2023
23rd Jan 20245:24 pmRNS2023 LTIP Grant
22nd Nov 20234:36 pmRNSHolding(s) in Company
30th Oct 20237:00 amRNSHPRA approval & distribution agreement in Spain
18th Sep 202310:40 amEQSHardman & Co Research on Tissue Regenix (TRX): Continuing postive momentum 1H'23
15th Sep 20234:30 pmRNSDirector/PDMR Shareholding
5th Sep 20237:01 amRNSNew sports medicine product launch
5th Sep 20237:00 amRNSInterim results
31st Aug 20231:45 pmRNSExercise of Options and Total Voting Rights
21st Aug 20237:00 amRNSNotice of interim results
17th Jul 20237:00 amRNSHalf-Year Trading Update
10th Jul 20237:00 amRNSDistribution agreement for OrthoPure® XT in the UK
25th May 20237:00 amRNSDistribution agreement with Australian Allografts
9th May 202312:00 pmRNSHolding(s) in Company
27th Apr 202312:35 pmRNSResult of AGM, Share Reorganisation &TVR
18th Apr 20237:00 amRNSProposed Share Reorganisation Timetable
5th Apr 20232:55 pmEQSHardman & Co Research on Tissue Regenix (TRX): Turning profitable and cash-generative
5th Apr 20237:00 amRNSCEO and CFO Share Purchases
30th Mar 20237:00 amRNSHolding(s) in Company
21st Mar 20237:00 amRNSFinal results for the year ended 31 December 2022
6th Mar 20237:00 amRNSNotice of results and Investor presentation
31st Jan 20237:01 amRNSTrading update for 2022
31st Jan 20237:00 amRNSChange of Adviser
18th Jan 202310:06 amRNSHolding(s) in Company
18th Jan 20237:00 amRNSChinese distribution agreement for OrthoPure® XT
7th Dec 20227:00 amRNSProduct launch in dCELL® division

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.